NOVO.B.DK

247.5

+0.22%↑

GMAB.DK

1,719

+0.7%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

NOVO.B.DK

247.5

+0.22%↑

GMAB.DK

1,719

+0.7%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

NOVO.B.DK

247.5

+0.22%↑

GMAB.DK

1,719

+0.7%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

NOVO.B.DK

247.5

+0.22%↑

GMAB.DK

1,719

+0.7%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

NOVO.B.DK

247.5

+0.22%↑

GMAB.DK

1,719

+0.7%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

Search

Coloplast A-S (Class B)

Затворен

451.6 0.92

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

445.8

Максимум

453.3

Ключови измерители

By Trading Economics

Приходи

522M

1.4B

Продажби

83M

7B

P/E

Средно за сектора

25.385

61.417

EPS

6.32

Дивидентна доходност

4.98

Марж на печалбата

19.835

Служители

16,983

EBITDA

309M

2.3B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+11.86% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.98%

2.40%

Следващи печалби

12.05.2026 г.

Следваща дата на дивидент

20.05.2026 г.

Следваща дата на екс-дивидент

18.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-17B

101B

Предишно отваряне

450.68

Предишно затваряне

451.6

Coloplast A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.03.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15.03.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15.03.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15.03.2026 г., 23:44 ч. UTC

Пазарно говорене
Значими събития в новините

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15.03.2026 г., 23:35 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15.03.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15.03.2026 г., 22:37 ч. UTC

Пазарно говорене

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15.03.2026 г., 22:18 ч. UTC

Пазарно говорене

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15.03.2026 г., 22:00 ч. UTC

Значими събития в новините

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15.03.2026 г., 22:00 ч. UTC

Значими събития в новините

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15.03.2026 г., 03:00 ч. UTC

Значими събития в новините

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Iran War Delivers Windfall to America's Oil Country -- WSJ

14.03.2026 г., 02:03 ч. UTC

Печалби

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14.03.2026 г., 01:32 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14.03.2026 г., 00:29 ч. UTC

Придобивния, сливания и поглъщания

13D Filings -- Barrons.com

13.03.2026 г., 22:27 ч. UTC

Пазарно говорене
Значими събития в новините

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13.03.2026 г., 22:13 ч. UTC

Пазарно говорене
Значими събития в новините

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13.03.2026 г., 22:04 ч. UTC

Пазарно говорене
Значими събития в новините

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13.03.2026 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

13.03.2026 г., 20:50 ч. UTC

Пазарно говорене
Значими събития в новините

Financial Services Roundup: Market Talk

13.03.2026 г., 20:02 ч. UTC

Пазарно говорене

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13.03.2026 г., 19:50 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13.03.2026 г., 19:35 ч. UTC

Значими събития в новините

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Coloplast A-S (Class B) Прогноза

Ценова цел

By TipRanks

11.86% нагоре

12-месечна прогноза

Среден 901.38 DKK  11.86%

Висок 1,056 DKK

Нисък 720 DKK

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Coloplast A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

2

Купи

4

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat